0000 GMT - Sonic Healthcare may have reiterated its earnings guidance alongside its 1H result today, but Barrenjoey thinks good news may be on the cards from the pathology services provider. Sonic expects FY 2025 Ebitda of A$1.70 billion-A$1.75 billion when currency swings are stripped out. At the midpoint of that range, guidance implies a 52% skew towards 2H, analyst Anshul Baruah says. That is lower than the skew in FY 2019, before Sonic's results got a boost from Covid-19 testing revenues. It suggests Sonic is more likely to achieve the upper end of its Ebitda guidance, Barrenjoey says. Sonic is down 2.3% today. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
February 19, 2025 19:00 ET (00:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.